Drexler Ingo, Staib Caroline, Sutter Gerd
Institute for Molecular Virology, München, Germany.
Curr Opin Biotechnol. 2004 Dec;15(6):506-12. doi: 10.1016/j.copbio.2004.09.001.
Safety-tested modified vaccinia virus Ankara (MVA) has been established as a potent vector system for the development of candidate recombinant vaccines. The versatility of the vector system was recently demonstrated by the rapid production of experimental MVA vaccines for immunization against severe acute respiratory syndrome associated coronavirus. Promising results were also obtained in the delivery of Epstein-Barr virus or human cytomegalovirus antigens and from the clinical testing of MVA vectors for vaccination against immunodeficiency virus, papilloma virus, Plasmodium falciparum or melanoma. Moreover, MVA is considered to be a prime candidate vaccine for safer protection against orthopoxvirus infections. Thus, vector development to challenge dilemmas in vaccinology or immunization against poxvirus bio-threat seems possible, yet the right choice should be made for a most beneficial use.
经过安全性测试的改良安卡拉痘苗病毒（MVA）已被确立为开发候选重组疫苗的有效载体系统。最近，通过快速生产用于预防严重急性呼吸综合征相关冠状病毒的实验性MVA疫苗，证明了该载体系统的多功能性。在递送爱泼斯坦-巴尔病毒或人巨细胞病毒抗原以及对用于预防免疫缺陷病毒、乳头瘤病毒、恶性疟原虫或黑色素瘤的MVA载体进行临床试验方面也取得了有前景的结果。此外，MVA被认为是更安全预防正痘病毒感染的主要候选疫苗。因此，开发载体以应对疫苗学中的难题或针对痘病毒生物威胁进行免疫似乎是可行的，但为了实现最有益的用途，应做出正确的选择。
